Sleep Medications: Safe Use, Alternatives, and Dependence

Insomnia: When to Consider Medication

Insomnia disorder — difficulty initiating or maintaining sleep with daytime impairment at least 3 nights/week for ≥3 months — affects 10–15% of adults chronically. Before considering pharmacotherapy, cognitive behavioral therapy for insomnia (CBT-I) should be offered as first-line treatment. CBT-I is more effective than any sleep medication for long-term outcomes.

When medication is used, it should be short-term (ideally 2–4 weeks), combined with sleep hygiene measures, and selected based on the patient's insomnia pattern and comorbidities.

---

Z-Medicines (Non-Benzodiazepine GABA-A Modulators)

Medicines: Zolpidem (Ambien, Ambien CR), zaleplon (Sonata), eszopiclone (Lunesta)

Mechanism: Bind the same GABA-A receptor site as benzodiazepines but with more selective affinity for alpha-1 subunit (sedation) vs alpha-2/3 subunits (anxiolysis, muscle relaxation).

FDA-approved: Short-term treatment of insomnia characterized by difficulty initiating sleep (immediate-release) or maintaining sleep (extended-release).

Zolpidem specifics:

Immediate-release: 5–10 mg (women require lower dosing — 5 mg — due to slower metabolism)

Extended-release (Ambien CR): For sleep maintenance

FDA lowered recommended doses in 2013 due to next-morning impairment affecting driving

Complex sleep behaviors (Black Box Warning, 2019): Sleepwalking, sleep-driving, sleep-eating — sometimes with no memory. Discontinue if these occur.

Do not combine with alcohol (CNS depression)

Zaleplon: Shortest acting (1 hour half-life) — can be taken in the middle of the night if ≥4 hours of sleep remain.

Eszopiclone: Longer-acting; FDA-approved without a strict duration limit; can cause metallic/bitter taste.

---

Benzodiazepines

Medicines used for insomnia: Temazepam (Restoril), triazolam, estazolam

Not recommended for long-term insomnia treatment. Cause rapid tolerance (within days to weeks), rebound insomnia upon discontinuation, next-day sedation, falls (especially elderly — Beers Criteria), impaired driving.

When benzodiazepines remain appropriate: Short-term insomnia during acute stress, alcohol withdrawal, adjunct in anxiety-driven insomnia.

---

Melatonin

Mechanism: Melatonin is a neurohormone produced by the pineal gland that signals circadian darkness. Exogenous melatonin acts on MT1/MT2 receptors to advance sleep phase and signal sleep onset.

Most effective for: Circadian rhythm disorders — jet lag, shift work sleep disorder, delayed sleep phase syndrome. Also useful for sleep onset difficulties where circadian phase is delayed.

Evidence for insomnia: Modest — reduces sleep onset latency by 7–12 minutes on average. Much weaker than other hypnotics for severe insomnia.

Key points:

Lower doses (0.5–1 mg) taken 2–3 hours before target bedtime are often more physiologically appropriate than high OTC doses (5–10 mg)

Not a controlled substance; available OTC

Appears safe for long-term use; no evidence of dependence

Ramelteon (Rozerem): Prescription MT1/MT2 agonist with higher receptor affinity than melatonin. Only FDA-approved prescription medication for insomnia without DEA scheduling (non-controlled). Modest efficacy.

---

Orexin Receptor Antagonists (Newest Class)

Medicines: Suvorexant (Belsomra), lemborexant (Dayvigo)

Mechanism: Block orexin/hypocretin receptors that promote wakefulness. Unlike GABA enhancers (z-medicines, benzodiazepines), these promote sleep by reducing wake drive rather than sedating. Sometimes described as "turning off" wakefulness rather than "turning on" sleep.

Advantages: Generally well tolerated; sleep architecture preserved; less respiratory depression concern.

Side effects: Next-morning drowsiness, sleep paralysis, complex sleep behaviors (rare).

---

OTC Sleep Aids

Most OTC sleep aids contain antihistamines (diphenhydramine or doxylamine) that cause sedation. Tolerance develops rapidly (within 3–4 days). The Beers Criteria advises against these in adults ≥65 due to anticholinergic effects and fall risk.

---

CBT-I: Why It's Better Than Pills

Cognitive Behavioral Therapy for Insomnia (CBT-I) addresses the perpetuating factors that maintain chronic insomnia:

Sleep restriction therapy: Build sleep pressure by restricting time in bed

Stimulus control: Re-associate the bed with sleepiness only

Sleep hygiene education

Cognitive restructuring: Address catastrophizing about sleep

Relaxation techniques

CBT-I produces sustained improvements lasting years, while medication effects end when the medicine stops. Available via therapist, online programs (Sleepio, Somryst — FDA-cleared digital therapeutic), and guided self-help.